NDC 0990-7922 Dextrose

Dextrose Monohydrate

NDC Product Code 0990-7922

NDC 0990-7922-02

Package Description: 24 POUCH in 1 CASE > 1 BAG in 1 POUCH > 250 mL in 1 BAG

NDC 0990-7922-03

Package Description: 24 POUCH in 1 CASE > 1 BAG in 1 POUCH > 500 mL in 1 BAG

NDC 0990-7922-09

Package Description: 12 POUCH in 1 CASE > 1 BAG in 1 POUCH > 1000 mL in 1 BAG

NDC 0990-7922-25

Package Description: 24 BAG in 1 CASE > 250 mL in 1 BAG

NDC 0990-7922-53

Package Description: 24 POUCH in 1 CASE > 1 BAG in 1 POUCH > 250 mL in 1 BAG

NDC 0990-7922-55

Package Description: 18 POUCH in 1 CASE > 1 BAG in 1 POUCH > 500 mL in 1 BAG

NDC 0990-7922-61

Package Description: 32 POUCH in 1 CASE > 1 BAG in 1 POUCH > 150 mL in 1 BAG

NDC Product Information

Dextrose with NDC 0990-7922 is a a human prescription drug product labeled by Icu Medical Inc.. The generic name of Dextrose is dextrose monohydrate. The product's dosage form is injection, solution and is administered via intravenous form.

Labeler Name: Icu Medical Inc.

Dosage Form: Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Dextrose Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • DEXTROSE MONOHYDRATE 5 g/100mL
  • DEXTROSE MONOHYDRATE 5 g/100mL

Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • WATER (UNII: 059QF0KO0R)
  • WATER (UNII: 059QF0KO0R)

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Intravenous - Administration within or into a vein or veins.
  • Intravenous - Administration within or into a vein or veins.

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Icu Medical Inc.
Labeler Code: 0990
FDA Application Number: NDA016367 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: NDA - A product marketed under an approved New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 07-15-2019 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2020 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions. Values = ‘Y’ or ‘N’.

* Please review the disclaimer below.

Dextrose Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

Other

Dextrose Injection, USPFlexible Plastic Container                                                                                                                 Rx only

Description

Dextrose Injection, USP solutions are sterile and nonpyrogenic. They are parenteral solutions containing various concentrations of dextrose in water for injection intended for intravenous administration.Each 100 mL of 5% Dextrose Injection, USP, contains dextrose, hydrous 5 g in water for injection. The caloric value is 170 kcal/L. The osmolarity is 252 mOsmol/L (calc.), which is slightly hypotonic.Each 100 mL of 10% Dextrose Injection, USP, contains dextrose, hydrous 10 g in water for injection. The caloric value is 340 kcal/L. The osmolarity is 505 mOsmol/L (calc.), which is hypertonic.The pH for both concentrations is 4.3 (3.2 to 6.5).The solutions contain no bacteriostat, antimicrobial agent or added buffer and each is intended only as a single-dose injection. When smaller doses are required the unused portion should be discarded.The solutions are parenteral fluid and nutrient replenishers.Dextrose, USP is chemically designated D-glucose monohydrate (C6H12O6 • H2O), a hexose sugar freely soluble in water. It has the following structural formula:Water for Injection, USP is chemically designated H2O.The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period.

Clinical Pharmacology

When administered intravenously, these solutions provide a source of water and carbohydrate.Isotonic and hypertonic concentrations of dextrose are suitable for parenteral maintenance of water requirements when salt is not needed or should be avoided.Solutions containing carbohydrate in the form of dextrose restore blood glucose levels and provide calories. Carbohydrate in the form of dextrose may aid in minimizing liver glycogen depletion and exerts a protein-sparing action. Dextrose injected parenterally undergoes oxidation to carbon dioxide and water.Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirements range from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production).Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na+) plays a major role in maintaining physiologic equilibrium.

Indications And Usage

Intravenous solutions containing dextrose are indicated for parenteral replenishment of fluid and minimal carbohydrate calories as required by the clinical condition of the patient.

Contraindications

Dextrose Injection without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur.

Warnings

Excessive administration of potassium-free solutions may result in significant hypokalemia.The intravenous administration of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.The risk of dilutional states is inversely proportional to the electrolyte concentrations of administered parenteral solutions. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions.

Precautions

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.Do not administer unless solution is clear and container is undamaged. Discard unused portion.Carcinogenesis, Mutagenesis, Impairment of Fertility: Studies with Dextrose Injection, USP have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.Pregnancy: Teratogenic effectsPregnancy Category C. Animal reproduction studies have not been conducted with dextrose. It is also not known whether dextrose can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Dextrose should be given to a pregnant woman only if clearly needed.Nursing Mothers: Caution should be exercised when Dextrose Injection, USP is administered to a nursing mother.Pediatric Use: The safety and effectiveness in the pediatric population are based on the similarity of the clinical conditions of the pediatric and adult populations. In neonates or very small infants the volume of fluid may affect fluid and electrolyte balance.Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants.In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolarity and possible intracerebral hemorrhage.Geriatric Use: An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Adverse Reactions

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

Overdosage

In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. (See WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS.)

Dosage And Administration

  • The dose is dependent upon the age, weight and clinical condition of the patient.As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia.Drug InteractionsAdditives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. (See PRECAUTIONS.)INSTRUCTIONS FOR USETo Open:Tear outer wrap at notch and remove solution container. If supplemental medication is desired, follow directions below before preparing for administration.To Add Medication1.Prepare additive port.2.Using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. Withdraw needle after injecting medication.3.The additive port may be protected by covering with an additive cap.4.Mix container contents thoroughly.Preparation for Administration(Use aseptic technique)1.Close flow control clamp of administration set.2.Remove cover from outlet port at bottom of container.3.Insert piercing pin of administration set into port with a twisting motion until the set is firmly seated. NOTE: When using a vented administration set, replace bacterial retentive air filter with piercing pin cover. Insert piercing pin with twisting motion until shoulder of air filter housing rests against the outlet port flange.4.Suspend container from hanger.5.Squeeze and release drip chamber to establish proper fluid level in chamber.6.Attach venipuncture device to set.7.Open clamp to expel air from set and venipuncture device. Close clamp.8.Perform venipuncture.9.Regulate rate of administration with flow control clamp.WARNING: Do not use flexible container in series connections.

How Supplied

Dextrose Injection, USP is supplied in single-dose flexible plastic containers in various sizes and concentrations as shown in the accompanying Table.ICU Medical is transitioning NDC codes from "0409" to "0990) labeler code. Both NDC codes are expected to be in the market for a period of time.NDC No. ProductContainer size(mL)0409-7922-61Manufactured by ICU Medical, Inc., Lake Forest, Illinois, 60045, USA5% Dextrose Injection, USP1500990-7922-615% Dextrose Injection, USP1500409-7922-53Manufactured for ICU Medical, Inc., Lake Forest, Illinois, 60045, USA5% Dextrose Injection, USP2500990-7922-535% Dextrose Injection, USP2500409-7922-025% Dextrose Injection, USP2500990-7922-025% Dextrose Injection, USP2500409-7922-035% Dextrose Injection, USP5000990-7922-035% Dextrose Injection, USP5000409-7922-555% Dextrose Injection, USP5000990-7922-555% Dextrose Injection, USP5000409-7922-09,5% Dextrose Injection, USP10000990-7922-09,5% Dextrose Injection, USP10000409-7923-205% Dextrose Injection, USP250990-7923-205% Dextrose Injection, USP250409-7923-365% Dextrose Injection, USP500990-7923-365% Dextrose Injection, USP500409-7923-135% Dextrose Injection, USP500990-7923-135% Dextrose Injection, USP500409-7923-235% Dextrose Injection, USP1000990-7923-235% Dextrose Injection, USP1000409-7923-375% Dextrose Injection, USP1000990-7923-375% Dextrose Injection, USP1000409-7930-0210% Dextrose Injection, USP2500990-7930-0210% Dextrose Injection, USP2500409-7930-0310% Dextrose Injection, USP5000990-7930-0310% Dextrose Injection, USP5000409-7930-0910% Dextrose Injection, USP10000990-7930-0910% Dextrose Injection, USP1000Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing.Revised: August, 2018EN-4685icumedical

* Please review the disclaimer below.